IL17A and neoplasm: Second, we asked whether IL-17 could improve ICI responsiveness also in an intrinsically resistant tumor scenario and applied the YUMM1.7 mouse model, which was reported to lack response to ICI (Ptendel, Cdkn2adel, BRATV600E-mutant melanoma21).